Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Abdominal (ABD) Infection Clear all
Active, not recruiting Phase 4 Interventional

The PASTDUe Nutrition Ecosystem Project (PASTDUe)

NCT05127109
View directory record Official record
Conditions
Diet, Healthy, Food, Nutrition, Intensive Care, Abdominal Trauma, Surgery, Intra-abdominal Infection, Sepsis, Ischemic Bowel, Vascular, Penetrating Abdominal Trauma, Enteral Feeding, Oral
Interventions
Nutrition Ecosystem pathway, Comparator
Combination Product · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Phase 3 Interventional Results available

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

NCT01069900
View directory record Official record
Conditions
Intraabdominal Infections
Interventions
Moxifloxacin (Avelox, BAY12-8039), Ertapenem, Amoxicillin/Clavulanate, Moxifloxacin placebo, Ertapenem placebo, Amoxicillin/Clavulanate placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
3 Months to 17 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
San Diego, California • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Results available

Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses

NCT00284739
View directory record Official record
Conditions
Abdominal Abscess, Pelvic Abscess
Interventions
Alteplase, saline
Drug · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

NCT02759588
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
Interventions
Olvi-Vec, Platinum-doublet with or without bevacizumab
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Newport Beach, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 23, 2026, 11:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626
View directory record Official record
Conditions
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm
Interventions
STAR0602
Drug
Lead sponsor
Marengo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Loma Linda, California • Sacramento, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Jul 23, 2026, 11:42 PM EDT
Terminated Not applicable Interventional

Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis

NCT01441271
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
Ileal diversion and lavage, total abdominal colectomy
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jul 23, 2026, 11:42 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Jul 23, 2026, 11:42 PM EDT
Recruiting No phase listed Observational

Myriad™ Augmented Soft Tissue Reconstruction Registry

NCT05243966
View directory record Official record
Conditions
Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, Lower Extremity Wound, Pilonidal Sinus, Anal Fistula, Hidradenitis Suppurativa, Pressure Injury
Interventions
Myriad Matrix™ and Myriad Morcells™
Device
Lead sponsor
Aroa Biosurgery Limited
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Phase 3 Interventional Results available

Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

NCT01499290
View directory record Official record
Conditions
Complicated Intra-Abdominal Infection
Interventions
CAZ-AVI, Metronidazole, Meropenem
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Chula Vista, California • San Diego, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Jul 23, 2026, 11:42 PM EDT
Recruiting Phase 2 Interventional

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

NCT05639647
View directory record Official record
Conditions
Gram-negative Bacterial Infections
Interventions
ATM-AVI, BAT
Drug
Lead sponsor
Pfizer
Industry
Eligibility
9 Months to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Results available

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

NCT03217136
View directory record Official record
Conditions
Complicated Intra-Abdominal Infection
Interventions
Ceftolozane/Tazobactam, Metronidazole, Meropenem, Placebo for Metronidazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
7 Days to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Not applicable Interventional

SUpPress SSI - Single Use Negative Pressure Wound Therapy (NPWT) to Reduce Surgical Site Infections

NCT03816293
View directory record Official record
Conditions
Surgical Site Infection, Obesity, Diabetes, Cesarean Section Complications
Interventions
Negative Pressure Wound Therapy
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
3,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Jul 23, 2026, 11:42 PM EDT
Not yet recruiting Not applicable Interventional

Barbed Suture vs Non-Barbed Closure for Emergency Exploratory Laparotomy RCT

NCT06043414
View directory record Official record
Conditions
Laparotomy, Dehiscence Wound, Surgical Site Infections, Trauma Abdomen, Emergency General Surgery
Interventions
triclosan-coated barbed suture, triclosan-coated non-barbed suture, Non-coated non-barbed suture
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

EHR-based Decision Support for Pediatric Acute Abdominal Pain in Emergency Care

NCT02633735
View directory record Official record
Conditions
Appendicitis
Interventions
Appy CDS
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
5 Years to 20 Years
Enrollment
5,940 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Oakland, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Jul 23, 2026, 11:42 PM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections

NCT01110382
View directory record Official record
Conditions
Abscess, Intra-Abdominal, Abdominal Abscess, Abdomen, Acute, Abdominal Pain, Appendicitis, Rupture, Infection, Intestinal Perforation, Peritonitis, Ileus
Interventions
Doripenem, Meropenem placebo, Meropenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
San Diego, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Jul 23, 2026, 11:42 PM EDT
Terminated Not applicable Interventional Results available

Prevention of Wound Complications After Cesarean Delivery in Obese Women Utilizing Negative Pressure Wound Therapy

NCT00654641
View directory record Official record
Conditions
Surgical Wound Dehiscence, Wound Infection
Interventions
Negative pressure wound closure, Standard wound closure
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Charleston, West Virginia • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Not applicable Interventional

Treatment of Abdominal Abscesses With or Without Fibrinolysis

NCT01597336
View directory record Official record
Conditions
Abdominal Abscess, Tissue Plasminogen Activator
Interventions
Tissue plasminogen activator abscess flush, Saline flush of abscess
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 17 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

NCT03329092
View directory record Official record
Conditions
Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
Interventions
ATM-AVI, MTZ, MER, COL
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Tucson, Arizona • Torrance, California • Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Not applicable Interventional

Impact of Information Prescriptions on Medication Adherence in Emergency Department (ED) Patients

NCT01174706
View directory record Official record
Conditions
Patient Compliance, Medication Adherence, Medication Non-Adherence
Interventions
Information prescriptions
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
3,940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Jul 23, 2026, 11:42 PM EDT
Terminated Not applicable Interventional Results available

Irrisept Versus Standard of Care in the Prevention of Surgical Site Infections

NCT02255487
View directory record Official record
Conditions
Surgical Site Infection
Interventions
IrriSept System, No Intervention - Standard of Care (SoC) only
Device · Other
Lead sponsor
Irrimax Corporation
Industry
Eligibility
18 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

NCT01644643
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Shreveport, Louisiana • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intra-abdominal at Cesarean Section: A Randomized Controlled Trial

NCT01479712
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Normal Saline Irrigation
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Female only
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

NCT01265784
View directory record Official record
Conditions
Complicated Intra-abdominal Infection
Interventions
TP-434, Ertapenem, Placebo
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Long Beach, California • Denver, Colorado • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Jul 23, 2026, 11:42 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

NCT06794541
View directory record Official record
Conditions
Complicated Intra-abdominal Infections (cIAI)
Interventions
IV Eravacycline 2mg/kg, IV Eravacycline 1.5mg/kg
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
8 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 23, 2026, 11:42 PM EDT